🎤Dr. Leigh Terry (University of Alabama)In this episode of Concentrating on Chromatography, we sit down with Dr. Leigh Terry from the University of Alabama to explore one of the biggest challenges in environmental analysis today: understanding—and accurately measuring—PFAS in water systems.While most regulatory methods focus on a small number of compounds like PFOA and PFOS, there may be thousands of PFAS compounds in the environment—and much of that burden goes undetected.<h4>In this episode, we cover:</h4><ul><li>Why PFAS are called “forever chemicals” (and why that label is evolving)</li><li>The limitations of targeted LC-MS/MS methods</li><li>What the fluorine mass balance problem reveals about PFAS destruction</li><li>How combustion ion chromatography (CIC) helps measure total organofluorine</li><li>Why “99.99% removal” doesn’t always mean what you think</li><li>Where PFAS actually end up in wastewater treatment systems</li><li>The most effective technologies for PFAS removal today</li><li>Why drinking water may only account for ~20% of total PFAS exposure</li></ul><h4>Key Insight:</h4>Even when analyzing dozens of PFAS compounds, researchers may only be capturing a small fraction of total organic fluorine—raising major questions about how we monitor and regulate these contaminants.<h3>Video Transcription</h3>In this episode of Concentrating on Chromatography, Dr. Leigh Terry discusses PFAS contamination in drinking water, the analytical challenges associated with measuring these compounds, current treatment technologies, and future directions for monitoring and regulation. The conversation highlights how analytical chemistry, environmental engineering, and public health intersect in addressing one of today's most discussed classes of emerging contaminants.<h4>Understanding PFAS and Their Significance</h4><h5>The University of Alabama Water Quality Research Center</h5>Dr. Leigh Terry is part of the University of Alabama's Center for Water Quality Research. The center operates an analytical laboratory focused on drinking water quality and the detection of contaminants at extremely low concentrations.The laboratory specializes in:<ul><li>Drinking water analysis</li><li>Organic contaminants</li><li>Emerging contaminants</li><li>PFAS monitoring</li><li>Water quality research</li></ul>Their work supports both research initiatives and practical solutions for water utilities and environmental agencies.<h4>Why Focus on PFAS?</h4>Although PFAS compounds have existed since the 1940s, public awareness has increased dramatically only in recent years.According to Dr. Terry, several factors contributed to the rapid growth of PFAS research:<ul><li>Increased media attention</li><li>New regulatory initiatives</li><li>Growing evidence of human exposure</li><li>Expanding research opportunities</li><li>Greater understanding of potential health risks</li></ul>PFAS are not new contaminants. Rather, society is only beginning to understand their prevalence in the environment and their potential impacts on human health.<h4>The Development of Standardized PFAS Methods</h4>One major advancement in PFAS analysis has been the development of standardized EPA methods.These methods allow:<ul><li>Consistent testing procedures</li><li>Comparable results between laboratories</li><li>Regulatory monitoring</li><li>Reliable data interpretation</li></ul>Dr. Terry notes that many of these standardized approaches began appearing around 2018–2019, providing a common framework for analytical laboratories and researchers.<h4>How Large Is the PFAS Universe?</h4>Many people are familiar with PFOA and PFOS, two of the most heavily studied PFAS compounds. However, these represent only a small fraction of the broader PFAS family.PFOA and PFOS are often referred to as:<ul><li>Legacy PFAS compounds</li><li>Original PFAS contaminants</li><li>Early commercial PFAS chemicals</li></ul>The challenge is that even minor modifications to molecular structure create entirely new PFAS compounds.Researchers estimate:<ul><li>Thousands of PFAS compounds exist</li><li>Some estimates exceed 10,000 compounds</li><li>Exact numbers depend on how PFAS are defined</li></ul>Scientific debate continues regarding classification and definition, making precise counting difficult.<h4>Why PFAS Are Called "Forever Chemicals"</h4>Dr. Terry notes that the phrase "forever chemicals" has become widely used, although she suggests the terminology could benefit from rebranding.PFAS persistence results from two key chemical properties.<h5>1. Amphiphilic Structure</h5>PFAS molecules contain:<ul><li>A water-loving (hydrophilic) head group</li><li>A water-repelling (hydrophobic) fluorinated tail</li></ul>This unusual combination allows PFAS to partition between:<ul><li>Water</li><li>Solids</li><li>Air-water interfaces</li><li>Foam</li></ul>Unlike many organic compounds, PFAS can interact effectively with multiple environmental phases.<h5>2. Extremely Strong Carbon–Fluorine Bonds</h5>The carbon–fluorine bond is among the strongest bonds in organic chemistry.As Dr. Terry explains:<ul><li>Large amounts of energy are required to break these bonds</li><li>Natural degradation processes are often ineffective</li><li>Destruction can require highly aggressive treatment conditions</li></ul>These properties make PFAS extremely persistent in both environmental systems and biological organisms.<h4>Toxicity, Regulations, and Environmental Behavior</h4><h5>Understanding PFAS Toxicity</h5>One of the biggest challenges in PFAS regulation is the incomplete understanding of toxicity.Dr. Terry explains that EPA regulations generally consider three factors:<ul><li>Presence in drinking water sources</li><li>Toxicity to humans</li><li>Availability of practical treatment options</li></ul>While some PFAS compounds are known to be harmful, many others remain insufficiently studied. Furthermore, PFAS often occur as mixtures rather than individual compounds.This creates important scientific questions:<ul><li>What is the toxicity of individual PFAS?</li><li>What is the toxicity of PFAS mixtures?</li><li>How should cumulative exposure be evaluated?</li></ul>These uncertainties continue to drive active research.<h4>What Happens to PFAS in Wastewater Treatment Plants?</h4>PFAS do not behave like many conventional contaminants.Rather than remaining fully dissolved in water, they often accumulate at interfaces such as:<ul><li>Water-solid interfaces</li><li>Water-air interfaces</li><li>Foam layers</li><li>Biological solids</li></ul>As a result:<ul><li>Some PFAS accumulate in biosolids</li><li>Some partition into foam</li><li>Some remain in treated effluent</li></ul>Their distribution depends on wastewater composition and treatment processes.<h4>Regulatory Monitoring and Targeted LC-MS Analysis</h4>Current EPA regulations focus on targeted analysis of specific PFAS compounds.Examples include:<ul><li>PFOA</li><li>PFOS</li></ul>Drinking water regulations currently establish maximum contaminant levels (MCLs) for these compounds at extremely low concentrations.Advantages of targeted LC-MS analysis include:<ul><li>Clearly defined analytes</li><li>Established regulatory limits</li><li>High analytical sensitivity</li><li>Reliable quantitation</li></ul>However, limitations remain:<ul><li>Only a small subset of PFAS is measured</li><li>Many PFAS compounds remain undetected</li><li>Total PFAS burden may be underestimated</li></ul>As Dr. Terry notes, targeted analysis provides only part of the overall picture.<h4>The Fluorine Mass Balance Problem</h4>One of the most important concepts discussed in the interview is fluorine mass balance.When PFAS degrade, fluorinated fragments may remain in the environment.This creates a critical question:Are treatment technologies truly destroying PFAS, or merely transforming them into shorter-chain PFAS compounds?To answer this, researchers perform fluorine mass balance calculations using:<ul><li>Targeted PFAS analysis</li><li>Fluoride measurements</li><li>Total organic fluorine measurements</li></ul>A successful destruction process should ultimately convert PFAS into fluoride ions rather than simply producing smaller PFAS molecules.<h4>Advanced Analysis, Treatment Technologies, and Future Directions</h4><h5>Combining Targeted and Bulk Fluorine Measurements</h5>Dr. Terry's group complements targeted LC-MS analysis with measurements of total organic fluorine.Approaches include:<ul><li>Absorbable Organic Fluorine (AOF)</li><li>Extractable Organic Fluorine (EOF)</li><li>Combustion Ion Chromatography (CIC)</li></ul>In these methods:<ul><li>Organic fluorine is captured</li><li>Samples are combusted</li><li>Released fluoride is quantified</li></ul>This provides insight into total fluorinated content, although contributions may originate from sources beyond PFAS, including pharmaceuticals and consumer products.<h4>Surprising Findings from Combined Analysis</h4>One important finding from wastewater studies was that targeted PFAS measurements accounted for only a small fraction of total organic fluorine.Dr. Terry reports that:<ul><li>Approximately 4% of measured AOF could be explained by targeted PFAS compounds</li><li>The majority of organic fluorine remained unidentified</li></ul>This suggests that environmental fluorine chemistry is considerably more complex than currently represented by routine monitoring programs.<h4>Preventing PFAS Contamination in the Laboratory</h4>PFAS analysis requires exceptionally strict quality control.Dr. Terry's laboratory routinely:<ul><li>Tests every new batch of SPE cartridges</li><li>Tests carbon tubes before use</li><li>Uses DI water blanks</li><li>Verifies consumables labeled as PFAS-free</li><li>Collects field blanks</li><li>Monitors analytical blanks throughout workflows</li></ul>These practices help prevent contamination from laboratory materials and consumables, a common challenge in ultra-trace PFAS analysis.<h4>Current PFAS Treatment Technologies</h4>Three technologies currently dominate PFAS removal in drinking water treatment:<ul><li>Granular Activated Carbon (GAC)</li><li>Ion Exchange Resins</li><li>Reverse Osmosis (RO)</li></ul>Selection depends on:<ul><li>PFAS concentration</li><li>Water quality</li><li>Local operating conditions</li><li>Utility infrastructure</li></ul>Although many emerging technologies are being investigated, these remain the most widely implemented solutions.<h4>Membrane Filtration and Pretreatment</h4>Dr. Terry collaborates with colleagues studying membrane-based PFAS treatment.Her own work focuses on pretreatment through biological filtration.The strategy involves:<ul><li>Removing natural organic matter</li><li>Reducing membrane fouling</li><li>Improving membrane performance</li><li>Extending operational efficiency</li></ul>This integrated approach demonstrates how multiple treatment technologies can work together to improve PFAS removal.<h4>Regional Monitoring Projects</h4>The University of Alabama team participates in EPA-supported monitoring efforts along the Gulf Coast.Their observations indicate:<ul><li>PFAS rarely occur alone</li><li>Multiple PFAS compounds frequently co-occur</li><li>Contamination often originates from identifiable point sources</li></ul>Examples include:<ul><li>Industrial facilities</li><li>Manufacturing operations</li><li>Military installations</li><li>Carpet manufacturing facilities</li></ul>Source identification remains a critical component of environmental monitoring programs.<h4>Future Directions for PFAS Monitoring</h4>Looking ahead, Dr. Terry sees several opportunities for improvement.Desired advances include:<ul><li>In situ monitoring technologies</li><li>Portable detection systems</li><li>Reduced analytical complexity</li><li>Lower instrument costs</li><li>Less expensive consumables</li><li>Faster analysis workflows</li></ul>Current PFAS testing requires substantial expertise, specialized instrumentation, and rigorous quality control, making widespread implementation challenging.<h4>Dr. Terry's Perspective on Long-Term Solutions</h4>When asked what major PFAS challenge she would most like to solve, Dr. Terry offered a broader perspective.Rather than focusing solely on remediation, she emphasized prevention.Her view is that society should:<ul><li>Better evaluate chemical toxicity before commercialization</li><li>Assess risks before large-scale deployment</li><li>Reduce introduction of harmful compounds into the environment</li><li>Support utilities tasked with contaminant removal</li></ul>She notes that water utilities often bear the responsibility of removing contaminants they did not create, highlighting the need for broader societal and regulatory support.<h4>Final Thoughts</h4>Dr. Terry encourages consumers to:<ul><li>Learn where their drinking water originates</li><li>Read annual water quality reports</li><li>Stay informed about local water quality</li><li>Consider appropriate home filtration where needed</li></ul>At the same time, she emphasizes confidence in municipal water systems and the importance of continued investment in water quality research, monitoring, and treatment technologies.<h4>Conclusion</h4>PFAS remain one of the most complex challenges in environmental chemistry and water treatment. Through advanced analytical methods such as LC-MS/MS, combustion ion chromatography, fluorine mass balance approaches, and large-scale monitoring programs, researchers like Dr. Leigh Terry are helping improve our understanding of these persistent contaminants.The interview highlights that solving the PFAS challenge will require a combination of better analytical tools, improved treatment technologies, stronger regulatory frameworks, and a greater emphasis on prevention before contaminants enter the environment.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

PFAS in Water: Why We’re Missing 96% of the Problem

This study evaluates an immobilized enzyme reactor (IMER) containing peptide N-glycosidase from Rudaea cellulosilytica (PNGase Rc) for rapid online deglycosylation of intact glycoproteins. Human glycoproteins and therapeutic antibodies were used as model substrates to assess reactor performance.The PNGase Rc IMER efficiently removed complex sialylated and core-fucosylated glycans, simplifying protein characterization and glycosylation-site analysis. The approach offers a fast and effective solution for bioanalytical workflows, biopharmaceutical quality control, and stability testing of therapeutic proteins.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577">Online Deglycosylation of Monomeric Intact Proteins Using the PNGase Rc Immobilized-Enzyme Reactor</a></h4>Katarína Molnárová, Petr Novák, Jana Nováková, and Petr Pompach*ACS Omega 2026, 11, 17, 25724–25729<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acsomega.6c00577">https://doi.org/10.1021/acsomega.6c00577</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.<div>Protein glycosylation, in which monosaccharide units are attached to a protein backbone through enzymatic pathways, is involved in many important biochemical processes and is considered one of the most important post-translational modifications. <a href="javascript:void(0);">(1)</a> It affects not only the stability and secretion of proteins, cell–cell interactions, and receptor–ligand recognition mechanisms but also the biological activity, plasma half-life, immunogenicity, pharmacodynamics, and pharmacokinetics of biotherapeutics. <a href="javascript:void(0);">(2−5)</a> Therapeutical monoclonal antibodies (mAbs) are among the best known pharmaceuticals that are based on glycoproteins. <a href="javascript:void(0);">(6)</a> Over 90% of the mAbs are derived from immunoglobulin G (IgG), in which N-glycosylation occurs at Asn297 of the Fc region and is responsible for modulating immune responses and interactions with other proteins. <a href="javascript:void(0);">(7,8)</a> In cancer treatment, mAbs are used to increase the response of the immune system against the tumor cell, thus inhibiting the cancerous cell growth and helping with the destruction and elimination. <a href="javascript:void(0);">(9)</a> Among the most commonly used mAbs are trastuzumab, bevacizumab, cetuximab, or margetuximab, which are used as an additional treatment for breast, colorectal, prostate, or lung cancer. <a href="javascript:void(0);">(10)</a>Mass spectrometry (MS)-based methods have become a method of choice in the analysis of mAbs that can provide information on sequence, post-translational modifications, and glycosylation profiles. <a href="javascript:void(0);">(11)</a> The enzymatic removal of the attached glycans from the protein backbone can reduce the complexity of the MS analysis, which can lead to a better understanding of the protein structure and modifications. In glycoproteomics, peptide-N-glycosidase F (PNGase F) is most used for glycan removal. It cleaves the linkage between the Asn residue and the N-acetylglucosamine (GlcNAc). <a href="javascript:void(0);">(12)</a> Jmeian et al. developed a monolithic PNGase F enzyme reactor fabricated in fused silica using a glycidyl methacrylate-co-ethylene dimethacrylate polymer and integrated it into an LC–MS workflow. The authors demonstrated the applicability of this system for the characterization of released neutral and acidic N-glycans by LC–MS analysis. <a href="javascript:void(0);">(13)</a> In another study, oriented immobilization of PNGase F onto a methacrylate-based monolithic support via glutathione-S-transferase–glutathione affinity coupling was employed to release N-glycans from denatured ribonuclease B and fetuin, as well as from native IgG. The released glycans and the corresponding deglycosylated proteins were subsequently analyzed by MALDI-MS. <a href="javascript:void(0);">(14)</a>Gramlich et al. showed the potential of PNGase Rc for N-glycan hydrolysis from both tryptic peptides and native glycoproteins at a low pH. The favorable properties of PNGase Rc, including activity at acidic pH and compatibility with reducing agents such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and denaturants like urea, make this enzyme well suited for online intact protein deglycosylation workflows. <a href="javascript:void(0);">(15,16)</a>In this report, we demonstrate the potential of the PNGase Rc IMER for rapid online deglycosylation of reduced monomeric glycoproteins, including human haptoglobin (Hp), human transferrin, anti-hHD6, and the therapeutic monoclonal antibodies trastuzumab and bevacizumab. The column retained its activity over more than 150 consecutive measurements, highlighting its robustness, suitability for repeated use in bioanalytical workflows, and applicability to pharmaceutical research and development.<h4>Experimental Section</h4><h5>Instrumentation and Experimental Conditions</h5>Automated sample handling and online deglycosylation were carried out using the HDX workstation (AffiPro, Czech Republic). The scheme of the system is shown on <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig1">Figure 1</a>. Samples of 50 mM ammonium bicarbonate buffer (pH 8.2) and 40 mM TCEP were placed in a sample tray at 4 °C. Ten microliters of the protein sample at a concentration of 0.03 mg/mL (0.3 μg per injection) were added to 40 μL of 50 mM ammonium bicarbonate and then transferred to 50 μL of 40 mM TCEP, pH 2.3. The disulfide bond reduction was carried at 40 °C for 5 min. The automated sample handling system injected 100 μL of the reaction mixture into the sample loop and switched the injection valve. Online deglycosylation was performed at room temperature using a PNGase Rc IMER (2.1 × 20 mm, AffiPro, Czech Republic) at a flow rate of 50 μL/min, followed by protein desalting on an OPTI-TRAP (0.5 × 2 mm) trap column (Optimize Technologies Inc., Oregon City, Oregon, USA) heated to 55 °C for 10 min with 0.2% formic acid delivered by an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1260+Infinity+III+isocratic+pump">Agilent 1260 Infinity III isocratic pump</a> (Agilent Technologies, Santa Clara, California, USA). By switching the trap valve, the protein was eluted by an acetonitrile gradient [(min)/% B] 0/10-9/10-16/70-16.5/90-17/90-18/10-23/10] delivered by the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1290+Infinity+II+LC">Agilent 1290 Infinity II HPLC</a> system (Agilent Technologies, Santa Clara, California, USA) at a flow rate of 20 μL/min. The mobile phase A consisted of 5% acetonitrile with 1% propan-2-ol and 0.1% formic acid, and the mobile phase B consisted of 95% acetonitrile with 1% propan-2-ol and 0.1% formic acid. The <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=8&amp;search=maXis+Q-TOF">maXis Q-TOF mass spectrometer</a> (Bruker Daltonics, Bremen, Germany) was operated in the survey MS mode in a mass range of m/z 50–3000. The acquired data were analyzed and processed by DataAnalysis 4.4 (Bruker Daltonics) and deconvoluted by UniDec <a href="javascript:void(0);">(17)</a> with the following parameters: data processing range, m/z 500–3000; charge range, 1–80; allowed mass range, 1,000–80,000; sampling rate, 10 Da; peak detection range, 500 Da; and peak detection threshold, 0.1.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_1_Schematic_of_the_automated_sample_handling_system_for_online_protein_deglycosylation_and_desalting_d4ee48b627.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 1. Schematic of the automated sample handling system for online protein deglycosylation and desalting. Protein samples, along with 50 mM ammonium bicarbonate and 40 mM TCEP stock solutions were placed in a sample tray chilled to 4 °C, while a second tray heated to 40 °C was used for disulfide bond reduction with TCEP buffer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_1_Schematic_of_the_automated_sample_handling_system_for_online_protein_deglycosylation_and_desalting_d4ee48b627.jpg 245w," sizes="100vw" width="1287" height="386"><h4>Results and Discussion</h4>The performance of the PNGase Rc IMER for the removal of complex N-glycans from intact proteins was tested using heavily glycosylated human Hp with four glycosylation sites (Asn184, Asn207, Asn211, and Asn241) <a href="javascript:void(0);">(18)</a> located at the β-chain and occupied by complex N-glycans terminated with sialic acid. Haptoglobin phenotype 2-1, used in this study, forms multimers consisting of β-chain and disulfide linked α1 and α2 chains. <a href="javascript:void(0);">(19)</a> The detection of glycosylated Hp β-chain requires reduction of the disulfide bonds by incubating the protein with a reducing reagent. TCEP is a common reducing reagent used for fast reduction of disulfide bonds at various pH levels. Forty degrees Celsius, the maximum temperature of the PAL tray, and 5 min of incubation were sufficient for complete reduction of Hp disulfide bonds. Individual signals corresponding to the glycosylated β-chain were observed in the m/z range of 35,800–37,400 (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig2">Figure 2</a>a). The limited resolution of the mass spectrometer did not allow assigning the different glycoforms of the haptoglobin β-chain, which is occupied by biantennary, triantennary, or tetraantennary glycans with various amounts of sialic acid and fucose. <a href="javascript:void(0);">(20,21)</a> The nonglycosylated α1 and α2 chains were observed at m/z 9190 and 15,940. When the PNGase Rc IMER was integrated into the flow system, a signal at m/z 27,270 was detected, demonstrating complete deglycosylation of the haptoglobin β-chain (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig2">Figure 2</a>b).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_2_A_Mass_spectrum_of_human_Hp_without_the_PN_Gase_Rc_IMER_implemented_in_the_system_0ecca84ed4.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 2. (A) Mass spectrum of human Hp without the PNGase Rc IMER implemented in the system. The base peak signals of the spectrum correspond to both α1 and α2 chains. The signal of the β chain is spread across its different glycoforms. (B) Mass spectrum of human Hp with the PNGase Rc IMER implemented in the system. The signal of the deglycosylated β chain is higher compared to its glycosylated form and observed only at m/z 27,270. This indicates complete removal of glycans from the Hp β chain." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_2_A_Mass_spectrum_of_human_Hp_without_the_PN_Gase_Rc_IMER_implemented_in_the_system_0ecca84ed4.jpg 245w," sizes="100vw" width="2015" height="913">In a previous study by Krenkova et al., the PNGase F IMER was used for deglycosylation of IgG, RNase B, and bovine fetuin with follow-up mass spectrometry detection of both released glycans and intact proteins using MALDI-TOF MS. <a href="javascript:void(0);">(14)</a> The authors demonstrated an effective method for rapid protein deglycosylation, which, however, requires additional sample handling prior to mass spectrometry measurement. The other study by Jmeian et al., which focused on released N-glycans, implemented a PNGase F IMER with online LC–MS detection. <a href="javascript:void(0);">(13)</a> The authors show the effectiveness of the method by identifying many different glycans released from a single protein or from a complex plasma mixture. Our approach is not directly intended for released N-glycan analysis; instead, it demonstrates the ability to measure intact proteins after rapid online deglycosylation using PNGase Rc at low pH. Samples prepared immediately prior to mass spectrometry analysis using the automated sample-handling platform can reduce variability associated with autosampler residence time, as some proteins may undergo degradation or precipitation during storage in the autosampler.Although all glycoproteins in this study were effectively deglycosylated, the method’s efficiency depends on the characteristics of the individual glycoprotein. Therefore, optimizing method parameters─including the isocratic flow rate, glycoprotein incubation time with TCEP, and/or the addition of denaturing reagent─may improve the overall efficiency of the deglycosylation process.The PNGase Rc IMER stability over a series of injections was tested by using the trastuzumab antibody. The measurements were carried out with the enzyme column kept at the laboratory temperature. As shown in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig5">Figure 5</a>, the results indicate that the column performance remained stable over the course of the 150 measurements, and no glycosylated form of the trastuzumab antibody heavy chain was detected. The activity of PNGase Rc in the presence of 5% acetonitrile and 5% propan-2-ol was evaluated using a bottom-up approach with human 2–1 haptoglobin, which was online-digested by a coimmobilized nepenthesin-2/pepsin IMER. In the absence of an organic solvent, the peptide IEKVVLHPNYSQVD remained fully deglycosylated throughout 30 injections. In contrast, in the presence of organic solvent, a marked loss of enzymatic activity was observed after only a few injections (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.6c00577/suppl_file/ao6c00577_si_001.pdf">Figure 2</a>).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_5_Monitoring_the_stability_and_performance_of_PN_Gase_Rc_IMER_4a9b5a9c53.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 5. Monitoring the stability and performance of PNGase Rc IMER. Trastuzumab heavy chain was completely deglycosylated after 150 injections." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_5_Monitoring_the_stability_and_performance_of_PN_Gase_Rc_IMER_4a9b5a9c53.jpg 170w," sizes="100vw" width="996" height="918"><h4>Conclusions</h4>Here, we demonstrate the potential of the PNGase Rc IMER for the online removal of N-glycans from intact monomeric glycoproteins reduced with TCEP. The column showed high sensitivity toward Hp, which has multiple glycosylation sites with various glycan structures, confirming its suitability for the profiling of complex glycoproteins. Bevacizumab and trastuzumab exhibited similar glycosylation profiles, with core-fucosylated biantennary glycans being the most abundant. Online deglycosylation with the PNGase Rc column resulted in a complete removal of the glycans from the heavy chains of both antibodies, proving that the column can be used for the rapid online deglycosylation of intact therapeutic mAbs. Moreover, the column remained stable over 150 measurements without any loss of activity, even when it was maintained at laboratory temperature. The significantly reduced reaction time, together with full automation and the absence of manual handling steps, substantially improves analytical throughput compared to conventional off-line deglycosylation workflows. These findings highlight the potential of the PNGase Rc IMER in the development of glycoprotein-based biopharmaceuticals, where detailed structural characterization of the protein part is critical for quality control, monitoring batch-to-batch variability, and stability testing.</div>

Online Deglycosylation of Monomeric Intact Proteins Using the PNGase Rc Immobilized-Enzyme Reactor

In the week of June 29, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Thermo Fisher Scientific: Insights from an IC specialist: To be suppressed or not suppressed?</h5><ul><li>Tu, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6310">Registration</a></li></ul>Join Thermo Fisher’s Ask the Experts session to learn how suppressor technology impacts ion chromatography performance, sensitivity, reliability, maintenance, and troubleshooting.<h5>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</h5><ul><li>Tu, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6311">Registration</a></li></ul>Discover how ZenoTOF high-resolution mass spectrometry is accelerating single-cell proteomics and plasma biomarker discovery through enhanced sensitivity, throughput, and automation.<h5>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</h5><ul><li>Tu, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6052">Registration</a></li></ul>This webinar will discuss diffuse transmission and reflection UV/VIS measurements, including how to perform measurements with Agilent’s Cary 60 UV/VIS Spectrometer.<h5>4. Waters Corporation: Informatics series #33 Tips, Tricks and Best Practices</h5><ul><li>Th, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6315">Registration</a></li></ul>This interactive session revisits essential features, shortcuts, and practical techniques in Empower software that can streamline everyday laboratory work and reduce unnecessary effort.<h5>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</h5><ul><li>Th, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6313">Registration</a></li></ul>Discover how cyclic ion mobility spectrometry (cyclic IMS) improves characterization of GLP-1 analogues and therapeutic peptides, supporting development, quality control, and regulatory submissions.<h5>6. Agilent Technologies: Spectral Flow Cytometry Masterclass - Session 1</h5><ul><li>Fr, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6316">Registration</a></li></ul>Learn how full-spectrum flow cytometry enables high-dimensional cell analysis. Explore spectral flow technology, experimental design, and applications in immunology, oncology, and vaccine research.

Webinars LabRulezLCMS Week 27/2026

Article

Webinars

Video

Scientists

Environment

Water

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Phenomenex

Thermo Fisher Scientific

SelectScience

Wiley

SCIEX

Waters Corporation

As we aim to make our environment safer, it is important to detect contaminations at very low levels. Hundreds of pesticides are routinely used for crop protection across the globe and most of these pesticides can leach into our water systems. Therefore it is important to monitor these compounds down to very low levels in both environmental and drinking water. European regulations are under constant review, one good example is the proposed amendments to the Directive 2008/105/EC.
Given the challenges brought in by the new regulations, it is becoming ever so important to have sensitive and robust methodologies. The growing target list now include multiple pesticides groups such as pyrethroids, organochlorines and organophosphorus. 
Our recommendation for the GC amenable pesticides analysis is APGC. This technology allows analysts to reach lower levels than ever before. The APGC ionization is considered ‘soft‘ when compared with techniques such as EI, which means that less fragmentation is observed for many compounds. Reduced fragmentation simplifies pre-cursor ion selection, subsequently resulting in higher sensitivity and specificity in MS/MS analyses.
Join our webinar to find out how APGC could improve your methods with: 
<ul>
<li>Sensitivity</li>
<li>Selectivity</li>
<li>Robustness</li>
</ul>
You will also hear from the industry experts about their experiences about APGC and how it helps to advance them further and stay in line (or exceed) regulatory limits, while also dealing with throughput demands.
<blockquote>
Presenter: Rhys Jones (Principal Consulting Scientist, Waters Corporation)
</blockquote>
<blockquote>
Rhys has worked for Waters in research and development for 20 years with a strong focus on gas chromatography mass spectrometry. ​The early part of his career was spent developing and supporting the AutoSpec magnetic sector instrument. ​One of his current responsibilities is the research, development and support of the atmospheric pressure gas chromatography (APGC) chemical ionization source, which has allowed the full range of Waters’ mass spectrometry techniques to be applied to GC analyses.
</blockquote>
<blockquote>
Presenter: Janitha de Alwis (JD) (Senior Applications Chemist, Waters Corporation)
</blockquote>
<blockquote>
Janitha de Alwis (known as JD) is an applications chemist in the European demo lab, based in Wilmslow, UK. His main role focuses on application development work for the food and environmental sector. JD takes great pride in speaking to, and advising, many food and environmental customers. His position requires him to be reactive and proactive to the changes in the food industry, such as changing regulations, topical issues and food safety risks.
</blockquote>

Waters Corporation: Change the Game Part II - Pesticide Analysis with Atmospheric Pressure GC (APGC)

Change the Game Part II - Pesticide Analysis with Atmospheric Pressure GC (APGC)

Join our webinar to find out how APGC could improve your methods with: Sensitivity, Selectivity, Robustness.

Pesticide Analysis with Atmospheric Pressure GC (APGC)

Per- and polyfluoroalkyl substances (PFAS), also referred to as ‘forever chemicals’, are an increasing concern since they accumulate in the environment and may have some deleterious effects on human health.
In this webinar, Dr. Estelle Riche, Global Application Specialist from Merck KGaA, Darmstadt, Germany, will discuss the importance of reagent water quality in trace analyses of PFAS by LC-MS/MS. Dr. Riche will show data on the efficiency of a lab water purification system at removing traces of PFAS from tap water and delivering ultrapure water suitable for sensitive PFAS testing. This webinar will also offer guidance on how to select an optimal water purification solution for these analyses, including tips on how to prevent water contamination for optimal experimental results.
Key learning objectives
<ul>
<li>Understand the role of reagent water in PFAS analyses by LC-MS/MS
</li>
<li>Discover how water purification technologies play a role in PFAS removal
</li>
<li>Learn how to select the best water purification solution to suit your lab’s needs
</li>
</ul>
Who should attend?
<ul>
<li>Any scientist analyzing or planning to analyze PFAS
</li>
<li>Lab managers and anyone using or maintaining lab water purification systems
</li>
</ul>
<blockquote>
Presenter: Dr. Estelle Riche, PhD (Global Application Specialist, Merck KGaA, Darmstadt, Germany)
</blockquote>
<blockquote>
Dr. Estelle Riche holds an engineering degree in chemistry from ESCOM in France and a Ph.D. in chemistry from the University of North Carolina (UNC) in the USA. She started her career as a Professor at UNC, then joined Merck KGaA, Darmstadt, Germany eighteen years ago. She is currently Global Application Specialist for Lab Water Solutions and her responsibilities include understanding the potential impact of water quality on the results of laboratory analyses.
</blockquote>
<blockquote>
Presenter: Carrie Haslam (SelectScience)
</blockquote>
<blockquote>
Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics. Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.
</blockquote>

SelectScience: Is your lab water pure enough for sensitive PFAS analyses?

Is your lab water pure enough for sensitive PFAS analyses?

The importance of reagent water quality in trace analyses of PFAS by LC-MS/MS.

Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!
Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. 
We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. 
Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. 
The event will have three parts: 
<ul>
<li>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).
</li>
<li>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).
</li>
<li>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).
</li>
</ul>
<blockquote>
Presenter: Day Powell (Environmental Application Specialist , Agilent)
</blockquote>
<blockquote>
Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.
</blockquote>
<blockquote>
Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).
</blockquote>
<blockquote>
Presenter: Marcus Chadha (EMEA Applications Specialist Manager, Agilent) Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.
</blockquote>
<blockquote>
In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.
</blockquote>
<blockquote>
He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.
</blockquote>
<blockquote>
Presenter: Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)
</blockquote>
<blockquote>
Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.
</blockquote>
<blockquote>
His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.
</blockquote>
<blockquote>
Presenter: Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)
</blockquote>
<blockquote>
Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.
</blockquote>
<blockquote>
Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.
</blockquote>
<blockquote>
She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.
</blockquote>

Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

The development and expansion of analytical methods for per- and polyfluoroalkyl substances (PFAS) in food is essential for the continued monitoring of the United States (US) food supply and assessments of dietary intake.
In March of 2022, the European Union Reference Laboratory (EURL) for halogenated persistent organic pollutants (POPs) in Feed and Food released a guidance document covering priority PFAS of interest, including analytical method parameters and limits of quantification (LOQs). As a result, the Food and Drug Administration (FDA) began method extension work to incorporate ten new additional analytes to method C-010.02 including long chain perfluorosulfonic acids, fluorotelomer sulfonates, and perfluorooctane sulfonamide. In December of 2022, The European Union published Commission Regulation 2022/2388, establishing maximum levels for perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorohexane sulfonic acid (PFHxS) in certain foodstuffs, primarily fish, molluscs, crustaceans, and eggs. As a result, the FDA method was evaluated for performance in reaching EU required LOQs for both compliance and monitoring purposes. The FDA method was found to be able to reach all required LOQs for analytes in matrices with established maximum levels and with further method modifications, required LOQs could be met in fruits, vegetables, and milk.
Key Learning Points:
<ul>
<li>Understand the FDA’s approach for PFAS LOQs in various food matrices
</li>
<li>Learn about the EU reference lab guidance for PFAS in foods and how the FDA is taking a similar approach to food safety
</li>
<li>Take a deep dive into which PFAS are designated targets and which are being monitored for screening
</li>
</ul>
Who Should Attend:
<ul>
<li>Any scientists, lab analysts, food safety advocates, food manufacturers or anyone interested in food safety.</li>
</ul>
<blockquote>
Presenter: Susan Genualdi Ph.D. (Research Chemist, Food and Drug Administration)
</blockquote>
<blockquote>
Susan Genualdi is currently a Research Chemist in the Center for Food Safety and Applied Nutrition at the Food and Drug Administration. Her research over the last 12 years has focused on developing methods for the analysis of direct and indirect food additives in food and food packaging and for the last 6 years has focused on PFAS analysis in foods. Prior to her work at the FDA, she received her PhD in Analytical Chemistry at Oregon State University and was a postdoctoral fellow at Environment Canada.
</blockquote>
<blockquote>
Presenter: Richard F. Jack Ph.D. (Global Market Development Manager, Phenomenex)
</blockquote>
<blockquote>
Richard F. Jack, Ph.D. Richard is the Global Market Development manager for the environmental and food markets at Phenomenex corporation. He has over 18 yrs. experience with chromatography and mass spectrometry for the environmental, semiconductor, chemical, and pharmaceutical industries. Richard is a former EPA Scientific Advisor for the EPA’s panel on Hydraulic Fracturing, a coauthor for EPA 557 and 557.1 along with ASTM D8001 and updates to D4327 and D6919 methods. He is currently the Second Vice Chairman for the ASTM D19 subcommittee on water analysis. Richard received his Ph.D. in biochemistry and anaerobic microbiology from Virginia Tech University and Master’s in ecology from the University of Tennessee.
</blockquote>

Phenomenex: FDA’s Analytical Method for PFAS Detection

FDA’s Analytical Method for PFAS Detection

Understand the FDA’s approach for PFAS LOQs in various food matrices.

As studies on PFAS continue to advance, the analytical technology used to support research and testing continues to advance.
Detection requirements for PFAS have been getting more challenging as advisory and regulatory limits are constantly being updated. Not only a highly sensitive LC-MS/MS platform essential, but background contamination must be controlled. We will discuss advances in LC-MS/MS technology with enhancements in negative ion sensitivity from the Xevo TQ Absolute Mass Spectrometer, as well as tools for data management with waters_connect software, and provide insights on controlling laboratory background. Waters comprehensive PFAS analysis support allows for detection of target compounds at ultra-trace concentrations along with easier, more robust, and accurate options as PFAS analysis continues into the future.
Key Learning Topics
<ul>
<li>Improvements in sensitivity using negative ion detection
</li>
<li>Developing and successfully implementing an LC-MS/MS method
</li>
<li>Tools for managing data (isomers, isotopes and more)
</li>
</ul>
Who should attend
<ul>
<li>PFAS Program Managers
</li>
<li>Laboratory Managers
</li>
<li>Analytical Scientists
</li>
<li>Quality Assurance Managers
</li>
</ul>
<blockquote>
Presenter: Gordon Fujimoto (PhD Group Leader, Chemical Analysis Applications, Waters Corporation)
</blockquote>
<blockquote>
Gordon Fujimoto is in Waters&#39; Americas mass spectrometry demonstration lab. He has worked on customer applications for twenty years for Waters. Currently, he is working with customers in the food, environment and materials areas on mass spectrometry applications.
</blockquote>

Waters Corporation: Trace-level Targeted Analysis for PFAS: The Challenges, and Best Practices for Success

Trace-level Targeted Analysis for PFAS: The Challenges, and Best Practices for Success

Advances in LC-MS/MS technology with enhancements in negative ion sensitivity from the Xevo TQ Absolute Mass Spectrometer.

Trace-level Targeted Analysis for PFAS - Best Practices

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5>10:40 - 11:20 Challenges in quantification of NDSRI’s</h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 2)

Developing targeted LC-MS/MS work to quantify key membrane receptors and antigens to evaluate drug targets and the effect of biotherapeutics is extremely challenging.
The expression levels of these proteins are often exceptionally low, the properties of these membrane proteins can limit the effectiveness of extraction and recovery, and the noises from biological matrices are typically high. Traditional methods often suffer from insufficient sensitivity and quantitative accuracy.
The focus of this webinar is to introduce an alternative method designed to implement more generic sample preparation steps in combination of strategic trap-elute chromatography, FAIMS selectivity, and sensitive LC-MS/MS acquisition utilizing selected reaction monitoring (SRM) on a premier triple quadrupole mass spectrometer. Prof. Qu and his team will demonstrate confident quantitation of various membrane receptors and antigens that are important to the biotherapeutics. The presented workflow will also demonstrate advantages to streamlining method development to increase productivity.
<blockquote>
Presenter: Prof. Jun Qu (Assistant Professor, State University New York (SUNY) Buffalo)
</blockquote>
<blockquote>
Jun Qu is a professor in the Department of Pharmaceutical Sciences of SUNY-Buffalo, and the director of Proteomics and Pharmaceutical Analysis Group in NY Center of Excellence in Life Sciences. His research is focused on the study of Clinical/Pharmaceutical Proteomics and Pharmaceutical Analysis by developing novel LC/MS-based strategies to markedly enhance the sensitivity, specificity, throughput and accuracy/precision for protein analysis in highly complex biological matrices. His research programs include i) highly sensitive and accurate characterization of biotherapeutics, targets and markers in pharmaceutical and clinical systems; ii) precise and large-scale global quantification of pathological proteomes using a novel MS1-based proteomic pipeline (IonStar); iii) sensitive identification, localization and quantification of post-translational modifications in tissue proteomes; iv) targeted investigation of marker proteins that are of high interests for clinical and pharmaceutical investigations. Qu lab is also one of the world leaders in LC-MS-based characterization of biotherapeutics in pre-clinical models. He has around 130 peer reviewed publications and &gt;70 grants funded as the principal investigator or co-investigator.
</blockquote>

Thermo Scientific: A new approach to perform ultra-sensitive, accurate, and absolute quantification of key membrane receptors and antigens in tissue and on cell surfaces

A new approach to perform ultra-sensitive, accurate, and absolute quantification of key membrane receptors and antigens in tissue and on cell surfaces

An alternative method designed to implement more generic sample preparation steps in combination of trap-elute chromatography, FAIMS and LC-MS/MS.

A new approach to perform ultra-sensitive, accurate

Food testing is an emerging trend in per- and polyfluoroalkyl substances (PFAS) analysis.
Join the discussion as SCIEX customers and industry experts explore how these “forever chemicals” have influenced our food testing and research, and how SCIEX OS software can help identify and quantify these compounds. Get insight into topics ranging from detecting PFAS in food packaging and baby food to analyzing the data with SCIEX OS software processing.
Join this event and learn:
<ul>
<li>All the latest PFAS testing trends and news
</li>
<li>What you need to know about PFAS in food
</li>
<li>How SCIEX OS software can help demystify PFAS and elevate food testing applications  
</li>
<li>Where other scientists and experts are focusing their PFAS research
</li>
<li>What to expect from SCIEX in the future when it comes to food testing, PFAS analysis and SCIEX OS software
</li>
</ul>
 
Day 1 agenda:
<h5>PFAS summit: phase I to phase II – drinking water and beyond</h5>
<ul>
<li>Dr. Craig Butt, Manager, Applied Market, SCIEX</li>
</ul>
<h5>PFAS in food: current state</h5>
<ul>
<li>Karl Oetjen, Senior Scientist, Technical Marketing, SCIEX</li>
</ul>
<h5>SCIEX OS software overview – unlocking the power of SCIEX OS software</h5>
<ul>
<li>Jessica Smith, Senior Marketing Development Specialist, Software, SCIEX</li>
</ul>
<h5>Food testing applications: latest trends</h5>
<ul>
<li>Gitte Barknowitz, Global Market Development Manager, Food and Environmental, SCIEX</li>
</ul>
<h5>From Analyst to SCIEX OS – a software story</h5>
<ul>
<li>Pradeep Dewapriya, Postdoctoral Research Fellow, The University of Queensland</li>
</ul>
<h5>PFAS analysis with SCIEX OS software: tips and tricks</h5>
<ul>
<li>Brad Patterson, Manager, Applications Support, SCIEX</li>
</ul>
<h5>PFAS in food matrices: developments in method validation with Phenomenex</h5>
<ul>
<li>Richard Jack, Global Market Development Manager, Phenomenex</li>
</ul>
<h5>The EPA&#39;s PFAS methods database: how this tool can help you</h5>
<ul>
<li>Antony Williams, Scientist, Center of Computational Toxicology and Exposure, US Environmental Protection Agency (EPA)</li>
</ul>
<h5>How Nestlé Switzerland developed and validated an LC-MS method for PFAS testing in food samples</h5>
<ul>
<li>Xanthippe Theurillat, Specialist R&amp;D, Nestlé Switzerland</li>
</ul>
<h5>SCIEX professional services: we&#39;re with you every step of the way</h5>
<ul>
<li>Mike Kobel, Director, Compliance services, SCIEX</li>
</ul>
<blockquote>
Presenter: Dr. Craig Butt
</blockquote>
<blockquote>
Presenter: Gitte Barknowitz
</blockquote>
<blockquote>
Presenter: Richard Jack
</blockquote>
<blockquote>
Presenter: Cheryl Murphy
</blockquote>
<blockquote>
Presenter: Antony Williams
</blockquote>
<blockquote>
Presenter: Yelena Sapozhnikova
</blockquote>
<blockquote>
Presenter: Karl Oetjen
</blockquote>
<blockquote>
Presenter: Pradeep Dewapriya
</blockquote>
<blockquote>
Presenter: Kevin Stroski
</blockquote>
<blockquote>
Presenter: Christian Lindh
</blockquote>
<blockquote>
Presenter: Ruben Kause
</blockquote>
<blockquote>
Presenter: Andrew Folkeson
</blockquote>
<blockquote>
Presenter: Jessica Smith
</blockquote>
<blockquote>
Presenter: Xanthippe Theurillat
</blockquote>
<blockquote>
Presenter: Brad Patterson
</blockquote>
<blockquote>
Presenter: Mike Kobel
</blockquote>
<blockquote>
Presenter: Andrew Savage
</blockquote>
<blockquote>
Presenter: Christel Nielsen
</blockquote>

SCIEX: PFAS summit: a scientific series (Day 1) - Part II: Food and environmental testing with SCIEX OS software

PFAS summit: a scientific series (Day 1) - Part II: Food and environmental testing with SCIEX OS software

How PFAS, these “forever chemicals” have influenced our food testing and research, and how SCIEX OS software can help identify and quantify these compounds.

PFAS summit: Food & Environ with SCIEX OS software (Day 1)

In this webinar, we will present end-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.
A broad portfolio in sample prep automation for protein therapeutics allows for highly reproducible results in the starting point of the analysis. A broad range of consumables and columns will be presented, leading into the subsequent separation via HPLC and detection by mass spectrometry.
The 6545XT AdvanceBio was particularly developed for intact protein analysis, and the ultra-high vacuum and large molecule autotune led to excellent sensitivity in denatured and native applications, allowing quantitation on the intact protein level as well as ADR calculations. Peptide mapping and glycan analysis results, along with the confirmation of oligonucleotide sequences using Q-TOF-based workflows, will be presented.
We will also highlight the ultrahigh performance of the novel 6495 triple quadrupole LC/MS system (G6495D) with MassHunter Workstation 12.1 for comprehensive multiplexed protein quantification. Artificial intelligence (AI)-based SWARM autotune and enhanced system features provide seamless protein quantification method optimization, ultimate analytical sensitivity, and high analytical precision as well as user-friendly instrument care and maintenance.
Lastly, we will show results from oligonucleotides and proteins analyzed on LC/MS single quadrupole and Time of Flight (TOF) instruments, the latest scientific applications, and recent method improvements.
<blockquote>
Presenter: Ian Edwards, Ph.D. (LC/TQ Portfolio Product Manager, Agilent Technologies Inc.)
</blockquote>
<blockquote>
Ian holds a PhD from the Centre for Proteome Research at the University of Liverpool. He has spent time as a pre- and post-sales MS applications specialist focused on MS imaging and proteomics, as a field marketing manager for -omics, and as a global pharmaceutical marketing manager. Ian joined Agilent recently as LC/TQ Product Manager.
</blockquote>
<blockquote>
Presenter: Russell Burge, Ph.D. (LC/SQ and LC/TOF Portfolio Product Manager, Agilent Technologies Inc.)
</blockquote>
<blockquote>
Russell earned a PhD in biochemistry and molecular biology from Scripps Research. He has extensive experience in the R&amp;D of biomolecules and biopharmaceuticals, and the implementation of automated workflows. Russell has acted as a Product Manager for various products in Life Science and Industrial Markets, and he currently manages the LC/MS SQ and LC/MS TOF product portfolios at Agilent.
</blockquote>
<blockquote>
Presenter: Christian Klein, Ph.D. (LC/Q-TOF Portfolio Product Manager, Agilent Technologies Inc.)
</blockquote>
<blockquote>
With an education in Chemistry, Chris Klein received his Ph.D. in 2005 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He joined Agilent Technologies in 2010 as the lead chemist in the LC/Q-TOF R&amp;D team. In 2018 Chris jointed the marketing team as Portfolio Product Manager, responsible for LC/Q-TOF and Ion Mobility.
</blockquote>
<blockquote>
Presenter: Róisín Murtagh (Editor, Wiley)
</blockquote>
<blockquote>
Róisín Murtagh has been an editor for Wiley Analytical Science since 2021. She holds a science degree from Maynooth University, Ireland, and an MSc in Medicinal Chemistry from the Open University, UK. With a background encompassing over 10 years of experience in analytical science, she has actively contributed to both industry and academic research.
</blockquote>

Wiley: Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

End-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.**

LCMS webinars focusing on LC/QQQ - page 22